Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06316843 · ClinicalTrials.gov registry record · Phase 2
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
A Phase 2 study of Long COVID and PASC Post Acute Sequelae of COVID 19, sponsored by Bateman Horne Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT06316843: Completed Phase 2 study of Long COVID and PASC Post Acute Sequelae of COVID 19, sponsored by Bateman Horne Center.
NCT06316843 is a Phase 2 study of Long COVID and PASC Post Acute Sequelae of COVID 19 that has completed, run by Bateman Horne Center. The registered enrollment target is 59 participants, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06316843, a Phase 2 study of Long COVID and PASC Post Acute Sequelae of COVID 19, has completed, sponsored by Bateman Horne Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.
Primary Outcome
The PROMIS Fatigue 7a will be automatically calculated to a T-score with a standard error of 4. Higher fatigue T-scores represent worse than average fatigue. The primary efficacy analysis will be the mean change from baseline (MCFB) to Week 12 in fatigue based on the weekly survey PROMIS Fatigue 7a T-scores. A mixed models for repeated measures (MMRM) procedure will be used to compare the MCFB between the treatment and placebo arm.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valacyclovir celecoxib dose 1
- DRUG Valacyclovir celecoxib dose 2
Study Locations (1)
Utah
- Bateman Horne Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2023-10-15 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
What the finished NCT06316843 record still lists
NCT06316843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Long COVID appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06316843 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06316843 about?
NCT06316843 is a clinical study titled "Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2". To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.
What is the current status of trial NCT06316843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2023-10-15. Estimated completion is 2024-10-31.
What conditions does trial NCT06316843 study?
This clinical trial studies the following conditions: Long COVID, PASC Post Acute Sequelae of COVID 19.
What interventions are being tested in trial NCT06316843?
The interventions under investigation include: Placebo (DRUG), Valacyclovir celecoxib dose 1 (DRUG), Valacyclovir celecoxib dose 2 (DRUG).
Who is sponsoring clinical trial NCT06316843?
This trial is sponsored by Bateman Horne Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06316843 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06316843's enrollment target sits among peer trials
59 32nd of 50 higher than 19 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NE3107 in Adults With Neurological Symptoms of Long COVID
RECRUITING · Phase 2
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI